美托洛尔缓释片、螺内酯片及盐酸贝那普利片联合治疗慢性心力衰竭的临床研究

Clinical Study of Metoprolol Sustained-Release Tablets, Spironolactone Tablets, and Benazepril Hydrochloride Tablets in the Treatment of Chronic Heart Failure

目的探究美托洛尔缓释片、螺内酯片及盐酸贝那普利片联合治疗慢性心力衰竭的效果。方法采用临床对照研究设计,研究期限为2017年4月至2019年7月,研究对象源自我院心血管内科62例慢性心力衰竭患者。根据治疗方法不同分为观察组(30例)和对照组(32例),对照组采用常规治疗,观察组加用美托洛尔缓释片、螺内酯片及盐酸贝那普利片联合治疗。治疗6个月,观察两组临床疗效、心功能(LVMI、CI、SV、LVEF、CO)、炎性指标(BNP、CRP)、不良反应。结果治疗6个月,观察组总有效率(93.33%)高于对照组(68.75%),差异显著(P<0.05)。心功能指标中,观察组LVMI低于对照组,但CI、SV、LVEF、CO则高于对照组,差异显著(P<0.05)。炎性指标中,观察组BNP、CRP水平低于对照组(P<0.05)。两组并发症总发生率比较无显著差异(P>0.05)。结论美托洛尔缓释片、螺内酯片及盐酸贝那普利片联合治疗慢性心力衰竭患者疗效较好,可有效改善心功能,降低炎性反应,且未新增不良反应。

Objective To explore the clinical study of metoprolol sustained-release tablets, spironolactone tablets and benazepril hydrochloride tablets in the treatment of chronic heart failure. Methods A total of 63 patients with chronic heart failure admitted to the Department of Cardiology in our hospital from April 2017 to July 2019 were selected. According to different treatment methods, they were divided into observation group(30 cases) and control group(32 cases). The control group received conventional treatment, and the observation group received metoprolol acid sustained-release tablets, spironolactone tablets and benazepril hydrochloride tablets on the basis of the control group. After 6 months of treatment, the clinical efficacy, cardiac function, inflammatory indexes, and adverse reactions of the two groups were observed. Results After 6 months of treatment, the total effective rate of the observation group was higher than that of the control group(93.33% vs. 68.75%, P<0.05).The left ventricular mass index of the observation group was lower than that of the control group, while the cardiac index, stroke volume, left ventricular ejection fraction, and cardiac output were higher than those of the control group(P<0.05). The levels of brain natriuretic peptideand C-reactive proteinn the observation group were lower than those in the control group(P<0.05). There was no significant difference in the total incidence of complications between the two groups(P>0.05). Conclusion The combination of metoprolol acid sustained-release tablets,spironolactone tablets and benazepril hydrochloride tablets has a good effect in patients with chronic heart failure, which can effectively relieve abnormal heart function and reduce the inflammatory response caused by chronic heart failure without new adverse reactions.